Details
Stereochemistry | RACEMIC |
Molecular Formula | C12H13I3N2O3 |
Molecular Weight | 613.9566 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CN(C(C)=O)C1=C(I)C(N)=C(I)C=C1I)C(O)=O
InChI
InChIKey=GSVQIUGOUKJHRC-UHFFFAOYSA-N
InChI=1S/C12H13I3N2O3/c1-5(12(19)20)4-17(6(2)18)11-8(14)3-7(13)10(16)9(11)15/h3,5H,4,16H2,1-2H3,(H,19,20)
Molecular Formula | C12H13I3N2O3 |
Molecular Weight | 613.9566 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Approval Year
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20 h |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: |
IOCETAMIC ACID plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: |
IOCETAMIC ACID plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 48 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 48 Sources: |
Other AEs: Ankle swelling, Feeling of warmth... Other AEs: Ankle swelling (6 patients) Sources: Feeling of warmth (10 patients) Chest pain (4 patients) Headache (14 patients) Paraesthesia (6 patients) Dizziness (10 patients) |
3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Other AEs: Vomiting, Nausea... Other AEs: Vomiting (1 patient) Sources: Nausea (14 patients) Watery diarrhoea (1 patient) Loose bowels (3 patients) Abdominal pain (12 patients) Eructation (19 patients) Flatus (15 patients) Nocturia (21 patient) Discolouration urine (5 patients) Itchy skin (3 patients) Blister (2 patients) Skin rash (1 patient) Bruising (2 patients) Wheezing (9 patients) Breathlessness (9 patients) Nocturnal dyspnoea (3 patients) |
4.5 g single, oral Highest studied dose |
unhealthy n = 1 |
Disc. AE: Skin infection... AEs leading to discontinuation/dose reduction: Skin infection (severe, 1 patient) Sources: |
3 g single, oral |
unhealthy n = 2 |
Disc. AE: Skin infection... AEs leading to discontinuation/dose reduction: Skin infection (2 patients) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 10 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 48 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 48 Sources: |
Feeling of warmth | 10 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 48 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 48 Sources: |
Headache | 14 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 48 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 48 Sources: |
Chest pain | 4 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 48 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 48 Sources: |
Ankle swelling | 6 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 48 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 48 Sources: |
Paraesthesia | 6 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 48 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 48 Sources: |
Skin rash | 1 patient | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Vomiting | 1 patient | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Watery diarrhoea | 1 patient | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Abdominal pain | 12 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Nausea | 14 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Flatus | 15 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Eructation | 19 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Blister | 2 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Bruising | 2 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Nocturia | 21 patient | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Itchy skin | 3 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Loose bowels | 3 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Nocturnal dyspnoea | 3 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Discolouration urine | 5 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Breathlessness | 9 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Wheezing | 9 patients | 3 g 2 times / day multiple, oral Highest studied dose Dose: 3 g, 2 times / day Route: oral Route: multiple Dose: 3 g, 2 times / day Sources: |
unhealthy, adult n = 49 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 49 Sources: |
Skin infection | severe, 1 patient Disc. AE |
4.5 g single, oral Highest studied dose |
unhealthy n = 1 |
Skin infection | 2 patients Disc. AE |
3 g single, oral |
unhealthy n = 2 |
Sample Use Guides
In Vivo Use Guide
Sources: http://newdruginformation.com/Cholebrine.htm
Administer 750 mg on the examination day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:17:43 GMT 2023
by
admin
on
Fri Dec 15 16:17:43 GMT 2023
|
Record UNII |
FA675Q0E3E
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28500
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
||
|
WHO-VATC |
QV08AC07
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
||
|
WHO-ATC |
V08AC07
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m6324
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
240-173-1
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
FA675Q0E3E
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
DB09403
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
16034-77-8
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
100000083404
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
Iocetamic acid
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
1451
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
3344
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
2347
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
27648
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200770
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
C65927
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
SUB08209MIG
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | |||
|
183830
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID2023149
Created by
admin on Fri Dec 15 16:17:43 GMT 2023 , Edited by admin on Fri Dec 15 16:17:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |